Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

635 - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Filip Kohutek

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

F. Kohutek1, B. Bystricky1, M. Kohutekova2

Author affiliations

  • 1 Department Of Oncology, Faculty Hospital Trencin, 911 71 - Trencin/SK
  • 2 Department Of Otorinolaryngology, Faculty Hospital Trencin, 911 71 - Trencin/SK
More

Resources

Abstract 635

Background

Induction of thrombocytosis and leukocytosis by tumour is a part of complex propagative strategy of malignancy. Activated leukocytes and thrombocytes produce several cytokines and enzymes that are crucial for tumour growth, invasion and dissemination. Therefore, leukocytosis and thrombocytosis might be a negative prognostic factor in malignancies.

Methods

Thrombocyte and leukocyte count were determined before the beginning of treatment. Patients with recent bleeding, elevated CRP or treated with best-supportive care were excluded. Relationship between thrombocytosis, leukocytosis and known negative prognostic factors was assessed. The impact of thrombocytosis and leukocytosis on progression-free survival (PFS) was determined. Chi- squared test, Kaplan- Meier and Cox- regression statistical analysis were used.

Results

500 patients with breast cancer (BC), ovarian cancer (OC), colorectal cancer (CrC), head and neck tumours (H&N) or lung cancer (LC) were included to our retrospective study. Thrombocytosis was more frequent in patients with metastatic cancer (whole population of patients) (17.4%, 95%CI :8.1125-26.7381, p = 0.0001); in patients with CrC (27%, 95% CI: 4.1554-47.9434, p = 0.0111); in patients with OC (27.7%, 95%CI: 6.5334- 46.4296, p = 0.0063) and in patients with H&N (46.9%, 95%CI: -9.5975-72.7755, p = 0.0459). Grading, estrogen- receptor (ER) progesteron- receptor (PR) and her2 status had no impact on frequency of thrombocytosis. Thrombocytosis had no impact on PFS. Leukocytosis was more frequent among patients with metastatic malignancies (10.6 %, 95%CI: 1.4352- 19.9713, p = 0.0174). This result reflected only in the subgroup of patients with H&N (46.9%, 95%CI: -9.5975- 72.7755, p = 0.0459). Grading, PR and her2 status had no impact on frequency of leukocytosis. Leukocytosis was more frequent in BC patients with negative ER status (18.7%, 95%CI: 1.0068- 40.1859, p = 0.0158). Leukocytosis shortened PFS in patients with LC (hazard ratio 2.1126, 95%CI:1.2712- 3.5109, p = 0.0014).

Conclusions

Leukocytosis might be a negative prognostic factor in patients with LC. More studies are needed to identify the subpopulation of leukocytes responsible for this effect.

Clinical trial identification

Legal entity responsible for the study

Faculty Hospital Trencin, Department of Oncology.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings